HYNES CONVENTION CENTER

Boston, Massachusetts
March 8–11, 2020

 

Conference Dates and Location: 
March 4–7, 2018 | Boston, Massachusetts
Abstract Number: 
465

ETRAVIRINE PHARMACOKINETICS IN TREATMENT-EXPERIENCED CHILDREN AGES 1- <6 YEARS

Author(s): 

Christine E. MacBrayne1, Richard Rutstein2, Ram Yogev3, Andrew Wiznia4, Lee Fairlie5, Bobbie Graham6, Carmelita Alvero7, Jack Moye8, Ellen Townley9, Herta Crauwels10, Xavier Woot de Trixhe10, Lotke Tambuyzer10, Simon Vanveggel10, Magda Opsomer10, Jennifer J. Kiser1

1University of Colorado Anschutz Medical Campus, Aurora, CO, USA,2Children's Hospital of Philadelphia, Philadelphia, PA, USA,3Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA,4Albert Einstein College of Medicine, Bronx, NY, USA,5University of the Witwatersrand, Acornhoek, South Africa,6Frontier Science & Technology Research Foundation, Inc, Amherst, NY, USA,7Harvard University, Cambridge, MA, USA,8National Institute of Child Health and Human Development, Bethesda, MD, USA,9NIAID, Rockville, MD, USA,10Janssen, Beerse, Belgium

Abstract Body: 

IMPAACT P1090 is a Phase I/II study of etravirine (ETR) pharmacokinetics (PK), dose- finding, and safety in antiretroviral (ARV) treatment-experienced HIV-infected children 1 to <6 yrs from the U.S., South Africa (SA) and Brazil.

Treatment-experienced children on a failing ARV regimen for ≥8 wk or on a treatment interruption for ≥4 wk with a history of virologic failure (VF) were enrolled into one of two age cohorts (2-<6 yr; 1-<2 yr). ETR was combined with at least two active ARVs, one of which was a ritonavir-boosted protease inhibitor (PI/r). ETR was dosed by weight-band. Participants 8-<10 kg received 75mg twice daily [bid]; 10-<20 kg, 100mg bid; and 20-<25 kg, 125mg bid. Tablets were swallowed whole or dispersed in liquid. All participants underwent 12-hr PK sampling on day 14 (±4 days). Participants with ETR AUC12h <10th percentile of adults (<2350 ng*hr/mL) had an individual ETR dose increase and repeat PK. For each cohort, PK and safety were confirmed in the first six participants before further enrolling at the same dose. The target geometric mean ETR AUC12h was 2713 to 6783 ng*hr/mL (60-150% of adult AUC12h). Criteria for acceptable safety included no suspected adverse drug reaction resulting in death, life-threatening toxicity, any grade 4 event, or ≥3 participants discontinuing due to grade ≥3 toxicity.

Twenty-one participants (nine each from SA and Brazil, three from U.S.) received ETR weight-band based doses. Demographics, ETR dosing and PK are shown for each cohort in the table. Both cohorts passed pre-determined PK and safety criteria, but seven (33%) children, all taking ETR dispersed, had an AUC12h of <2350 ng*hr/mL and underwent an ETR dose increase. Geometric mean ETR AUC12hr was significantly higher in participants that swallowed the tablet whole vs. dispersed, 7943 ng*hr/mL (n=6) vs. 2697 ng*hr/mL (n=15), respectively (p=0.0002). After a median (range) follow-up of 62 (9-234) weeks, three (14%) participants (2/3 with day 14 AUC12h <2350 ng*hr/mL) have discontinued due to VF. One participant discontinued due to a treatment-related toxicity (grade 4 lipase).

Weight-band based ETR dosing achieved predefined AUC12h targets in HIV-infected children receiving an ARV regimen including a PI/r, but 33%, all taking dispersed tablets, had AUC12h <10th percentile of the adult AUC12h. To date, ETR is well-tolerated and the rate of VF in these 21 treatment-experienced children is low.

Session Number: 
P-F3
Session Title: 
ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
Presenting Author: 
Jennifer Kiser
Presenter Institution: 
University of Colorado-AMC